| J Rakiiba Jackson, CNM | |
|
Dept. Of Health, Family Planning Program, Elainco Bldg., Est. Contant 78-123, St. Thomas, VI 00802 | |
| (340) 774-5256 | |
| (340) 774-7392 |
| Full Name | J Rakiiba Jackson |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | Dept. Of Health, Family Planning Program, Elainco Bldg., St. Thomas, Virgin Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386764272 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 1143 (Virgin Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| J Rakiiba Jackson, CNM Po Box 1317, St Thomas, VI 00804-1317 Ph: (340) 777-8804 | J Rakiiba Jackson, CNM Dept. Of Health, Family Planning Program, Elainco Bldg., Est. Contant 78-123, St. Thomas, VI 00802 Ph: (340) 774-5256 |
News Archive
InspireMD Ltd., a medical device company engaged in the development and commercialization of the mesh based MGuard(TM) stent systems, is proud to report that mesh-based protection, is now recommended for use in the new Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC). According to the latest European Society of Cardiology Guidelines, published at the ESC Congress last week, "Mesh-based protection may be considered for PCI of highly thrombotic or SVG lesions" - it has received a class IIb recommendation.
EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for the advanced chronic wound management market, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its new SilverStream(TM) solution for prescription use. The FDA also cleared DermaSept, an Over-the-Counter version of the SilverStream product.
The National Institute of Environmental Health Sciences (NIEHS) has awarded a five-year, $1.5 million grant extension to Columbia University's Mailman School of Public Health to fund research into the function of a biomarker for brain injury called Translocator Protein 18 kDa, better known as TSPO, in order to better understand its function in brain injury and inflammation and discover targets for therapy.
Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.
› Verified 3 days ago
Lynda Smith Murphree, ARNP, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1619 Sixth Street, St. Thomas, VI 00802 Phone: 340-244-1345 Fax: 340-777-6663 |